Company to pay US$60M for deceptive marketing with pelvic mesh
In this Dec. 20, 2018, photo, Dr. Jeffrey Clemons, a pelvic reconstructive surgeon, holds a sample of transvaginal mesh used to treat pelvic floor disorders and incontinence in women as he poses for a photo in Tacoma, Wash. (AP Photo/Ted S. Warren)
JACKSON, MISS. -- A company that failed to adequately inform women of dangerous side effects related to permanent pelvic mesh devices will be required to pay US$60 million, according to a settlement announced this week by state attorney generals across the U.S.
The money from C.R. Bard, Inc. and its parent company Becton, Dickinson and Company, will be spread out among 48 states and the District of Columbia. For example, Arizona will receive $1.15 million. Mississippi is set to receive around $840,000.
"C.R. Bard failed to disclose serious and life-altering risks of permanently implanted surgical mesh devices, leaving thousands of women to suffer," Mississippi Attorney General Lynn Fitch said in a statement. "This settlement holds Bard accountable for its deceptive business practices."
The Associated Press reached out to Becton, Dickinson and Company for comment Friday morning.
C.R. Bard Inc. is just the latest manufacturer of transvaginal mesh, a net-like implant used to treat stress urinary incontinence and pelvic organ prolapse, to be required by the court to pay a large sum.
In 2019, after patients reported serious complications -- including erosion of mesh through organs, pain during sexual intercourse, and voiding dysfunction -- the U.S. Food and Drug Administration banned sales of all mesh products used for pelvic organ prolapse repair.
In October of last year, Johnson & Johnson agreed to pay $117 million settlement with 41 states and the District of Columbia over similar allegations involving the mesh devices. In January, a judge ordered Johnson & Johnson to pay nearly $344 million in additional penalties for deceptive marketing of the product.
Stress urinary incontinence and pelvic organ prolapse are common conditions faced by women due to a weakening in their pelvic floor muscles caused by childbirth, age and other factors. Millions of women were implanted with transvaginal mesh before it was pulled from the market, Fitch said.
Along with paying the $60 million, C.R. Bard will be required to adhere to new requirements for marketing if the company chooses to sell the product again, including the need to disclose all potential complications associated with the product in marketing materials.